CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Cytomegalovirus Infections, Primary Immune Deficiency Disorder
CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults (CAYA) with refractory cytomegalovirus (CMV) infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. Funding Source: FDA OOPD
Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)
-
Children's Hospital Los Angeles, Los Angeles, California, United States, 90027
University of California San Francisco, San Francisco, California, United States, 94158
Indiana University, Indianapolis, Indiana, United States, 46202
Johns Hopkins, Baltimore, Maryland, United States, 21287
Washington University, Saint Louis, Missouri, United States, 63130
New York Medical College, Valhalla, New York, United States, 10595
Nationwide Children's Hosptial, Columbus, Ohio, United States, 43205
Children's Hospital of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104
Medical College of Wisconsin/Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States, 53226
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
1 Month to 79 Years
ALL
No
New York Medical College,
Mitchell S Cairo, MD, PRINCIPAL_INVESTIGATOR, New York Medical College
2026-12-31